Intellia Therapeutics, Inc. – NASDAQ:NTLA

Add to watchlist

$10.25

-1.72

-14.37%

Market closed

Open in 1 day

-53.59%

month

-53.59%

quarter

-62.29%

year

Market Cap	1.22B
Enterprise value	2.47B

P/E	-5.57
EV/Sales	47.48
EV/EBITDA	-5.40
Price/Sales	55.02
Price/Book	2.32
PEG ratio	0.08
EPS	-5.35

Revenue	52.60M
EBITDA	-512.35M
Income	-485.50M
Revenue Q/Q	129.53%
Revenue Y/Y	-1.62%

Profit margin	-909.78%
Oper. margin	-879.04%
Gross margin	0%
EBIT margin	-879.04%
EBITDA margin	-973.99%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Intellia Therapeutics Stock Forecast

M Q Y

Last Year

$39

Potential upside: 280.48%

Analysts Price target
Financials & Ratios estimates

Intellia Therapeutics, Inc. (NASDAQ:NTLA): Profit margin
Jun 2023	13.59M	-123.68M	-909.82%
Sep 2023	11.99M	-122.22M	-1019.21%
Dec 2023	-1.91M	-132.16M	6894.16%
Mar 2024	28.93M	-107.43M	-371.3%

Intellia Therapeutics, Inc. (NASDAQ:NTLA): Debt to assets
Jun 2023	1323240000	218.35M	16.5%
Sep 2023	1243349000	205.93M	16.56%
Dec 2023	1300977000	250.80M	19.28%
Mar 2024	1259589000	223.45M	17.74%

Intellia Therapeutics, Inc. (NASDAQ:NTLA): Cash Flow
Jun 2023	-90.32M	-34.53M	2.51M
Sep 2023	-101.38M	79.5M	19.10M
Dec 2023	-93.05M	45.93M	106.48M
Mar 2024	-120.66M	5.90M	59.99M

Intellia Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Intellia Therapeutics
Employees

Intellia Therapeutics, Inc. (NASDAQ:NTLA): Employee count
Sep 2023	598
Oct 2023	598
Nov 2023	598
Dec 2023	598
Jan 2024	598
Feb 2024	598
Mar 2024	526
Apr 2024	526
May 2024	526
Jun 2024	526
Jul 2024	526

Intellia Therapeutics
Hedge Funds Holdings Q1 2023

56.36% -43.64%

of NTLA is owned by hedge funds

186 -107

hedge funds hold NTLA stock

43.38M -34.52M

shares is hold by hedge funds

NTLA hedge funds holdings changes

Intellia Therapeutics
Insider Trading

Intellia Therapeutics, Inc. (NASDAQ:NTLA): Insider trades (number of shares)
Period	Buy	Sel
Jun 2023	0	5000
Jul 2023	0	2492
Oct 2023	0	265
Jan 2024	0	50528
Mar 2024	0	2902

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	4 Mar 2024	BASTA JAMES officer: EVP, General Counsel officer: EVP, General Counsel	Common Stock	2,297	$32.99	$75,778
Sale	4 Mar 2024	CLARK ELIANA officer: EVP, Chief Technical Officer officer: EVP, Chief Technical O..	Common Stock	605	$32.99	$19,959
Sale	8 Jan 2024	SEPP-LORENZINO LAURA officer: EVP, Chi..	Common Stock	1,608	$28.66	$46,085
Sale	8 Jan 2024	SEPP-LORENZINO LAURA officer: EVP, Chi..	Common Stock	1,608	$28.66	$46,085
Sale	8 Jan 2024	SEPP-LORENZINO LAURA officer: EVP, Chi..	Common Stock	667	$29.38	$19,596
Sale	8 Jan 2024	SEPP-LORENZINO LAURA officer: EVP, Chi..	Common Stock	667	$29.38	$19,596
Sale	3 Jan 2024	HICKS DEREK officer: EVP, Chief Business Officer officer: EVP, Chief Business Of..	Common Stock	3,877	$29.46	$114,216
Sale	3 Jan 2024	BASTA JAMES officer: EVP, General Counsel officer: EVP, General Counsel	Common Stock	3,805	$29.46	$112,095
Sale	3 Jan 2024	CLARK ELIANA officer: EVP, Chief Technical Officer officer: EVP, Chief Technical O..	Common Stock	307	$30.12	$9,247
Sale	3 Jan 2024	CLARK ELIANA officer: EVP, Chief Technical Officer officer: EVP, Chief Technical O..	Common Stock	4,301	$29.46	$126,707

NTLA insider trading transactions

Intellia Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 22 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 9 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 3 Aug 2023	Q2 2023 Earnings Call Transcript

NTLA earnings call transcripts

Intellia Therapeutics
Executives

Insider	Age	Compensation
Dr. John M. Leonard (1957) Pres, Chief Executive Officer & Director	68	$912,790
Dr. Laura Sepp-Lorenzino (1961) Executive Vice President & Chief Scientific Officer	64	$609,380
Mr. Glenn G. Goddard (1971) Executive Vice President, Chief Financial Officer & Treasurer	54	$562,450

Intellia Therapeutics
Latest News

Friday, 20 December 2024
14:00	Intellia Crashes 60% in a Year: How Should You Play the Stock?	zacks.com
Tuesday, 3 December 2024
16:01	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Tuesday, 26 November 2024
11:30	NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy	zacks.com
Monday, 25 November 2024
07:30	Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy	globenewswire.com
Friday, 22 November 2024
08:30	Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?	fool.com
Monday, 18 November 2024
22:57	Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)	seekingalpha.com
Saturday, 16 November 2024
10:16	Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis	globenewswire.com
Monday, 11 November 2024
08:30	Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus	seekingalpha.com
07:16	3 Fast-Growing Stocks Analysts See Doubling in Price	marketbeat.com
Friday, 8 November 2024
10:50	NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus	zacks.com
Thursday, 7 November 2024
14:49	Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript	seekingalpha.com
09:56	Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
07:30	Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress	globenewswire.com
Wednesday, 6 November 2024
09:45	Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?	fool.com
Tuesday, 5 November 2024
16:01	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Monday, 4 November 2024
08:00	This Beaten-Down Stock Could Soar by 354%, According to Wall Street	fool.com
Thursday, 31 October 2024
07:30	Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024	globenewswire.com
Monday, 28 October 2024
10:00	12 High-Growth Stocks That Could Deliver Parabolic Returns	fool.com
Friday, 25 October 2024
12:25	Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity	seekingalpha.com
Thursday, 24 October 2024
19:22	Why Intellia Therapeutics Stock Plummeted by 20% Today	fool.com
13:36	Intellia Therapeutics, Inc. (NTLA) Call to Discuss NTLA-2002 Phase 2 Study Results Transcript	seekingalpha.com
13:01	2 Biotech Stocks Making Big Moves	schaeffersresearch.com
12:43	Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?	benzinga.com
08:01	Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)	globenewswire.com
Thursday, 17 October 2024
11:05	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?	zacks.com
06:30	This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street	fool.com
Thursday, 10 October 2024
07:30	Intellia Therapeutics Announces New Date for Upcoming Investor Webcast	globenewswire.com
Wednesday, 9 October 2024
06:35	2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street	fool.com
Tuesday, 8 October 2024
14:12	NTLA Begins Phase III Study on Hereditary Angioedema Candidate	zacks.com
Monday, 7 October 2024
07:30	Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)	globenewswire.com

Ideas & Opinions

Seeking Alpha 15 Aug 2025

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
Seeking Alpha 18 Jul 2025

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'
Seeking Alpha 20 May 2025

I Missed The Quantum Rally - I Won't Miss The Next One
Seeking Alpha 5 May 2025

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
Seeking Alpha 25 Jan 2025

Undercovered Dozen: Virgin Galactic, Gold Fields, Matador Resources, EHang +
Seeking Alpha 17 Jan 2025

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Seeking Alpha 16 Jan 2025

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
Seeking Alpha 14 Jan 2025

Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade)
Seeking Alpha 13 Jan 2025

Intellia Therapeutics: Buying The Path To Commercialization
Seeking Alpha 27 Jun 2024

3 Biotech Stocks For The Second Half Of 2024

Frequently Asked Questions (FAQ)

What's the price of Intellia Therapeutics stock today?

One share of Intellia Therapeutics stock can currently be purchased for approximately $10.25.
When is Intellia Therapeutics's next earnings date?

Unfortunately, Intellia Therapeutics's (NTLA) next earnings date is currently unknown.
Does Intellia Therapeutics pay dividends?

No, Intellia Therapeutics does not pay dividends.
How much money does Intellia Therapeutics make?

Intellia Therapeutics has a market capitalization of 1.22B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 30.4% to 36.28M US dollars.
What is Intellia Therapeutics's stock symbol?

Intellia Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "NTLA".
What is Intellia Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Intellia Therapeutics?

Shares of Intellia Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Intellia Therapeutics's key executives?
Intellia Therapeutics's management team includes the following people:
- Dr. John M. Leonard Pres, Chief Executive Officer & Director(age: 68, pay: $912,790)
- Dr. Laura Sepp-Lorenzino Executive Vice President & Chief Scientific Officer(age: 64, pay: $609,380)
- Mr. Glenn G. Goddard Executive Vice President, Chief Financial Officer & Treasurer(age: 54, pay: $562,450)
How many employees does Intellia Therapeutics have?

As Jul 2024, Intellia Therapeutics employs 526 workers.
When Intellia Therapeutics went public?

Intellia Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 6 May 2016.
What is Intellia Therapeutics's official website?

The official website for Intellia Therapeutics is intelliatx.com.
Where are Intellia Therapeutics's headquarters?

Intellia Therapeutics is headquartered at 40 Erie Street, Cambridge, MA.
How can i contact Intellia Therapeutics?

Intellia Therapeutics's mailing address is 40 Erie Street, Cambridge, MA and company can be reached via phone at 857 285 6200.
What is Intellia Therapeutics stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Intellia Therapeutics in the last 12 months, the avarage price target is $39. The average price target represents a 280.48% change from the last price of $10.25.

Intellia Therapeutics, Inc.

intelliatx.com

Exchange:

NASDAQ

Full time employees:

526

Industry:

Biotechnology

Sector:

Healthcare

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

857 285 6200

40 Erie Street
Cambridge, MA 02139

CIK: 0001652130
ISIN: US45826J1051
CUSIP: 45826J105